Sarissa Capital Management
Sarissa Capital Management reported 10 stocks worth $153M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are INVA (26.2%), IRWD (23.8%) and AMRN (10.9%). Compared with Q2 2026, the fund trimmed AMRN.
Latest filing: what Sarissa Capital Management did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() INVA Innoviva Inc | $40.1M | 26.2% | 1.9M | No change | 8 of 8 | |
| 2 | ![]() IRWD Ironwood Pharmaceuticals Inc | $36.5M | 23.8% | 9.2M | No change | 8 of 8 | |
| 3 | ![]() AMRN Amarin Corp PLC | $16.7M | 10.9% | 1.3M | −386K (−23%) | 6 of 8 | |
| 4 | ![]() LNTH Lantheus Hldgs Inc | $16.6M | 10.8% | 167K | No change | 8 of 8 | |
| 5 | ![]() NBIX Neurocrine Biosciences Inc | $16.5M | 10.8% | 117K | No change | 8 of 8 | |
| 6 | ![]() CYTK Cytokinetics Inc | $15.1M | 9.8% | 229K | No change | 8 of 8 | |
| 7 | ![]() BHVN Biohaven Ltd | $7.8M | 5.1% | 582K | No change | 4 of 8 | |
| 8 | ![]() REGN Regeneron Pharmaceutical | $3.2M | 2.1% | 4,190 | No change | 5 of 8 | |
| 9 | ![]() VOR Vor Biopharma Inc Com New | $485K | 0.3% | 25K | No change | 5 of 8 | |
| 10 | ![]() BIIB Biogen Inc | $215K | 0.1% | 950 | No change | 2 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Sarissa Capital Management 13F FAQ
What does Sarissa Capital Management own?
Sarissa Capital Management reported 10 stocks worth $153M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are INVA (26.2%), IRWD (23.8%) and AMRN (10.9%). The table above lists every position in the filing (the top 10 without an account).
What did Sarissa Capital Management buy and sell in Q3 2026?
Compared with Q2 2026: 0 new positions, 0 added to, 1 trimmed and 0 sold out.
When will Sarissa Capital Management file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Sarissa Capital Management's portfolio worth?
The Q3 2026 filing reports $153M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.









